The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform

Joseph Wang - One of the best experts on this subject based on the ideXlab platform.

  • optimal cutoff point of Glutamate Decarboxylase Antibody titers in differentiating two subtypes of adult onset latent autoimmune diabetes
    Annals of the New York Academy of Sciences, 2004
    Co-Authors: Xiayu Li, Zhiguang Zhou, Gan Huang, Liting Yang, Xiang Chen, Joseph Wang
    Abstract:

    : The optimal cutoff point of Glutamate Decarboxylase Antibody (GAD-Ab) titers for differentiating two latent autoimmune diabetes (LADA) subtypes remains unclear. One hundred and forty-five GAD-Ab-positive patients screened from phenotypic type 2 diabetes were diagnosed as LADA. The clinical features were compared among LADA patients with different GAD-Ab titers. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic value of GAD-Ab titers and to define the optimal cutoff point. The heterogeneity of clinical features in LADA could be discriminated by five GAD-Ab titers, with maximal differences at the titer of 175 U/mL. The ROC curve analysis showed that the optimal cutoff point for discriminating two LADA subtypes was at the titer of 175 U/mL, with sensitivity and specificity of 54.5% and 92.1%, respectively. These findings demonstrated that the two clinically distinct subtypes of LADA can be optimally discriminated by the GAD-Ab titers.

Bengt Persson - One of the best experts on this subject based on the ideXlab platform.

  • Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity.
    The Journal of Clinical Endocrinology and Metabolism, 2010
    Co-Authors: Eva Örtqvist, Lynn M. Bekris, Barbara M. Brooks-worrell, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, Bengt Persson
    Abstract:

    Context: The previously reported absence of 65-kDa Glutamate Decarboxylase Antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an Antibody response to GAD65Ab or a longitudinal decline in anti-Id levels. Objective and Design: We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis - 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline - 12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses. Results: At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed ≥50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients ...

  • changes in 65 kilodalton Glutamate Decarboxylase Antibody specific antiidiotypic Antibody levels correlate with changes in c peptide levels and progression to islet cell autoimmunity
    Endocrinology, 2010
    Co-Authors: Eva Örtqvist, Lynn M. Bekris, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, Barbara Brooksworrell, Bengt Persson
    Abstract:

    This article appears in The Journal of Clinical Endocrinology & Metabolism. 10.1210/jc.2010-0785

  • Changes in GAD65Ab-specific antiidiotypic Antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity.
    The Journal of clinical endocrinology and metabolism, 2010
    Co-Authors: Eva Örtqvist, Barbara M. Brooks-worrell, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, L M Bekris, Bengt Persson
    Abstract:

    The previously reported absence of 65-kDa Glutamate Decarboxylase Antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an Antibody response to GAD65Ab or a longitudinal decline in anti-Id levels. We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis - 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline - 12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses. At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed ≥50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients who experienced a temporary increase in C-peptide levels. Anti-Id levels correlated significantly with glycated hemoglobin and C-peptide levels at 6 and 9 months (P values ranged from <0.001 to <0.05). In LADA patients receiving placebo, anti-Id levels declined in seven of nine patients, whereas four of five patients receiving 20 μg alum-formulated human recombinant GAD65 showed increasing anti-Id levels. Changes in anti-Id and C-peptide levels closely correlated (P < 0.0001). The significant decline in anti-Id levels (P = 0.03) in T2D patients developing T cell autoimmune responses supports our hypothesis that declining anti-Id levels are associated with developing islet autoimmunity. The close association between GAD65Ab-specific anti-Id levels and β-cell function may provide a novel marker for the progression of autoimmune diabetes.

Xiayu Li - One of the best experts on this subject based on the ideXlab platform.

  • optimal cutoff point of Glutamate Decarboxylase Antibody titers in differentiating two subtypes of adult onset latent autoimmune diabetes
    Annals of the New York Academy of Sciences, 2004
    Co-Authors: Xiayu Li, Zhiguang Zhou, Gan Huang, Liting Yang, Xiang Chen, Joseph Wang
    Abstract:

    : The optimal cutoff point of Glutamate Decarboxylase Antibody (GAD-Ab) titers for differentiating two latent autoimmune diabetes (LADA) subtypes remains unclear. One hundred and forty-five GAD-Ab-positive patients screened from phenotypic type 2 diabetes were diagnosed as LADA. The clinical features were compared among LADA patients with different GAD-Ab titers. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic value of GAD-Ab titers and to define the optimal cutoff point. The heterogeneity of clinical features in LADA could be discriminated by five GAD-Ab titers, with maximal differences at the titer of 175 U/mL. The ROC curve analysis showed that the optimal cutoff point for discriminating two LADA subtypes was at the titer of 175 U/mL, with sensitivity and specificity of 54.5% and 92.1%, respectively. These findings demonstrated that the two clinically distinct subtypes of LADA can be optimally discriminated by the GAD-Ab titers.

  • Optimal Cutoff Point of Glutamate Decarboxylase Antibody Titers in Differentiating Two Subtypes of Adult‐Onset Latent Autoimmune Diabetes
    Annals of the New York Academy of Sciences, 2004
    Co-Authors: Xiayu Li, Zhiguang Zhou, Gan Huang, Liting Yang, Xiang Chen, Jianxin Wang
    Abstract:

    : The optimal cutoff point of Glutamate Decarboxylase Antibody (GAD-Ab) titers for differentiating two latent autoimmune diabetes (LADA) subtypes remains unclear. One hundred and forty-five GAD-Ab-positive patients screened from phenotypic type 2 diabetes were diagnosed as LADA. The clinical features were compared among LADA patients with different GAD-Ab titers. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic value of GAD-Ab titers and to define the optimal cutoff point. The heterogeneity of clinical features in LADA could be discriminated by five GAD-Ab titers, with maximal differences at the titer of 175 U/mL. The ROC curve analysis showed that the optimal cutoff point for discriminating two LADA subtypes was at the titer of 175 U/mL, with sensitivity and specificity of 54.5% and 92.1%, respectively. These findings demonstrated that the two clinically distinct subtypes of LADA can be optimally discriminated by the GAD-Ab titers.

Zhiguang Zhou - One of the best experts on this subject based on the ideXlab platform.

  • elevated histone h3 acetylation is associated with genes involved in t lymphocyte activation and Glutamate Decarboxylase Antibody production in patients with type 1 diabetes
    Journal of Diabetes Investigation, 2019
    Co-Authors: Yanfei Wang, Jonathan Wisler, Kanhaiya Singh, Chao Wu, Qianjin Lu, Zhiguang Zhou
    Abstract:

    AIMS/INTRODUCTION: Genetic and epigenetic mechanisms have been implicated in the pathogenesis of type 1 diabetes, and histone acetylation is an epigenetic modification pattern that activates gene transcription. However, the genome-wide histone H3 acetylation in new-onset type 1 diabetes patients has not been well described. Accordingly, we aimed to unveil the genome-wide promoter acetylation profile in CD4+ T lymphocytes from type 1 diabetes patients, especially for those who are Glutamate Decarboxylase Antibody-positive. MATERIALS AND METHODS: A total of 12 patients with new-onset type 1 diabetes who were Glutamate Decarboxylase Antibody-positive were enrolled, and 12 healthy individuals were recruited as controls. The global histone H3 acetylation level of CD4+ T lymphocytes from peripheral blood was detected by western blot, with chromatin immunoprecipitation linked to microarrays to characterize the promoter acetylation profile. Furthermore, we validated the results of particular genes from chromatin immunoprecipitation linked to microarrays by using chromatin immunoprecipitation quantitative polymerase chain reaction, and analyzed the transcription level by real-time quantitative polymerase chain reaction. RESULTS: Elevated global histone H3 acetylation level was observed in type 1 diabetes patients, with 607 differentially acetylated genes identified between type 1 diabetes patients and controls by chromatin immunoprecipitation linked to microarrays. The hyperacetylated genes were enriched in biological processes involved in immune cell activation and inflammatory response. Gene-specific assessments showed that increased transcription of inducible T-cell costimulator was in concordance with the elevated acetylation in its gene promoter, along with positive correlation with Glutamate Decarboxylase Antibody titer in type 1 diabetes patients. CONCLUSIONS: The present study generates a genome-wide histone acetylation profile specific to CD4+ T lymphocytes in type 1 diabetes patients who are glutamic acid Decarboxylase Antibody-positive, which is instrumental in improving our understanding of the epigenetic involvement in autoimmune diabetes.

  • optimal cutoff point of Glutamate Decarboxylase Antibody titers in differentiating two subtypes of adult onset latent autoimmune diabetes
    Annals of the New York Academy of Sciences, 2004
    Co-Authors: Xiayu Li, Zhiguang Zhou, Gan Huang, Liting Yang, Xiang Chen, Joseph Wang
    Abstract:

    : The optimal cutoff point of Glutamate Decarboxylase Antibody (GAD-Ab) titers for differentiating two latent autoimmune diabetes (LADA) subtypes remains unclear. One hundred and forty-five GAD-Ab-positive patients screened from phenotypic type 2 diabetes were diagnosed as LADA. The clinical features were compared among LADA patients with different GAD-Ab titers. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic value of GAD-Ab titers and to define the optimal cutoff point. The heterogeneity of clinical features in LADA could be discriminated by five GAD-Ab titers, with maximal differences at the titer of 175 U/mL. The ROC curve analysis showed that the optimal cutoff point for discriminating two LADA subtypes was at the titer of 175 U/mL, with sensitivity and specificity of 54.5% and 92.1%, respectively. These findings demonstrated that the two clinically distinct subtypes of LADA can be optimally discriminated by the GAD-Ab titers.

  • Optimal Cutoff Point of Glutamate Decarboxylase Antibody Titers in Differentiating Two Subtypes of Adult‐Onset Latent Autoimmune Diabetes
    Annals of the New York Academy of Sciences, 2004
    Co-Authors: Xiayu Li, Zhiguang Zhou, Gan Huang, Liting Yang, Xiang Chen, Jianxin Wang
    Abstract:

    : The optimal cutoff point of Glutamate Decarboxylase Antibody (GAD-Ab) titers for differentiating two latent autoimmune diabetes (LADA) subtypes remains unclear. One hundred and forty-five GAD-Ab-positive patients screened from phenotypic type 2 diabetes were diagnosed as LADA. The clinical features were compared among LADA patients with different GAD-Ab titers. The receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic value of GAD-Ab titers and to define the optimal cutoff point. The heterogeneity of clinical features in LADA could be discriminated by five GAD-Ab titers, with maximal differences at the titer of 175 U/mL. The ROC curve analysis showed that the optimal cutoff point for discriminating two LADA subtypes was at the titer of 175 U/mL, with sensitivity and specificity of 54.5% and 92.1%, respectively. These findings demonstrated that the two clinically distinct subtypes of LADA can be optimally discriminated by the GAD-Ab titers.

  • Clinical characteristics and classification of 2128 outpatients with diabetes
    Journal of Central South University. Medical sciences, 2004
    Co-Authors: Hai-ying Qi, Zhiguang Zhou, Xia Li
    Abstract:

    OBJECTIVE: To determine the clinical characteristics of diabetic outpatients and their classification,and to provide some suggestions for diagnostics, education and follow-up of outpatients. METHODS: We analyzed the data of 2 128 outpatients recorded in the past year, and studied the clinical characteristics, distribution of types and relation between Glutamate Decarboxylase Antibody (GADA) and age, sex and duration. RESULTS: Of all the patients, 918 (43.1%) were new-onset, and 1883 (88.6%) aged 40 or older. Altogether 782(36.7%) of the patients were done with GADA examination and 4.2% of them were GADA positive. Twelve patients were type 1 diabetes and 764 were type 2 diabetes, respectively with 33.3% and 3.8% GADA positive. The prevalence of GADA positive was 5.1% for men and 3.2% for women (P > 0.05). The frequencies of GADA positive in patients with different duration (1 year, 5 years, 10 years and more) were 4.4%, 4.8%, 1.7% and 4.9% (P >0.05) respectively. CONCLUSION: The new-onset population of the studied patients is dominated by 40-year olds or older. Type 2 diabetes is the main type in the diabetes spectrum. The frequency of GADA positive is irrelevant to sex and duration.

Eva Örtqvist - One of the best experts on this subject based on the ideXlab platform.

  • Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity.
    The Journal of Clinical Endocrinology and Metabolism, 2010
    Co-Authors: Eva Örtqvist, Lynn M. Bekris, Barbara M. Brooks-worrell, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, Bengt Persson
    Abstract:

    Context: The previously reported absence of 65-kDa Glutamate Decarboxylase Antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an Antibody response to GAD65Ab or a longitudinal decline in anti-Id levels. Objective and Design: We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis - 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline - 12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses. Results: At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed ≥50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients ...

  • changes in 65 kilodalton Glutamate Decarboxylase Antibody specific antiidiotypic Antibody levels correlate with changes in c peptide levels and progression to islet cell autoimmunity
    Endocrinology, 2010
    Co-Authors: Eva Örtqvist, Lynn M. Bekris, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, Barbara Brooksworrell, Bengt Persson
    Abstract:

    This article appears in The Journal of Clinical Endocrinology & Metabolism. 10.1210/jc.2010-0785

  • Changes in GAD65Ab-specific antiidiotypic Antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity.
    The Journal of clinical endocrinology and metabolism, 2010
    Co-Authors: Eva Örtqvist, Barbara M. Brooks-worrell, Kristian Lynch, Jared Radtke, Ingrid Kockum, Carl-david Agardh, Corrado M. Cilio, Åsalinda Lethagen, L M Bekris, Bengt Persson
    Abstract:

    The previously reported absence of 65-kDa Glutamate Decarboxylase Antibody (GAD65Ab)-specific antiidiotypic antibodies (anti-Id) in type 1 diabetes (T1D) patients at clinical onset could be due to an inability to mount an Antibody response to GAD65Ab or a longitudinal decline in anti-Id levels. We investigated anti-Id levels in longitudinal samples obtained from T1D patients (n = 41) (clinical diagnosis - 12 months), and latent autoimmune diabetes in adults (LADA) patients (n = 32) who received alum-formulated human recombinant GAD65 (baseline - 12 months). We also determined anti-Id levels in a small cohort of Type 2 diabetes patients during their development of autoimmune T cell responses. At clinical onset T1D patients presented no or low anti-Id levels. However, 22/41 T1D patients showed ≥50% increase in GAD65Ab-specific anti-Id levels during follow-up; peaking at 3 (n = 1), 6 (n = 10), 9 (n = 10), or 12 (n = 1) months. Increasing anti-Id levels marked patients who experienced a temporary increase in C-peptide levels. Anti-Id levels correlated significantly with glycated hemoglobin and C-peptide levels at 6 and 9 months (P values ranged from <0.001 to <0.05). In LADA patients receiving placebo, anti-Id levels declined in seven of nine patients, whereas four of five patients receiving 20 μg alum-formulated human recombinant GAD65 showed increasing anti-Id levels. Changes in anti-Id and C-peptide levels closely correlated (P < 0.0001). The significant decline in anti-Id levels (P = 0.03) in T2D patients developing T cell autoimmune responses supports our hypothesis that declining anti-Id levels are associated with developing islet autoimmunity. The close association between GAD65Ab-specific anti-Id levels and β-cell function may provide a novel marker for the progression of autoimmune diabetes.